Behind Arkema’s ￥430 Million Claim: A Patent War Over Acrylic Acid Is Tearing Off the “Technical Fig Leaf” of China’s Chemical Giants

On November 15, 2025, a single announcement from Shanghai Huayi Group Corporation dropped like a depth charge into the capital markets. What began in March 2024 as a patent infringement lawsuit filed by French chemical titan Arkema has now reached a critical juncture: the plaintiff has amended its claims, placing the entire RMB 430 million compensation demand squarely on its wholly owned subsidiary, Shanghai Huayi New Materials Co., Ltd., while requiring Guangxi Huayi New Materials Co., Ltd. to bear joint liability for RMB 110 million of that sum.

This is no ordinary legal dispute—it is a head-on clash between global technological hegemony and China’s industrial ambition. It exposes a harsh truth: as Chinese chemical enterprises evolve from “followers” to “contenders,” and even attempt to become “leaders” in certain fields, global incumbents will not relinquish their technical moats without a fight. And this battle over the “method for preparing acrylic acid” is precisely where those tectonic tensions surface.

Why Are “Process Patents” So Lethal?

The two Chinese invention patents asserted by Arkema—No. 200780034079.8 and No. 201210384253.4, both titled “Method for Preparing Acrylic Acid”—may sound like routine process improvements at first glance. But a closer look reveals they are nothing short of arteries feeding the entire acrylic acid value chain.

Acrylic acid is a cornerstone of modern chemical industry, serving as the key raw material for superabsorbent polymers, acrylic ester coatings, adhesives, textile auxiliaries, and more. Globally, annual consumption exceeds ten million metric tons, with a market value in the tens of billions of dollars. The dominant production route—propylene oxidation—has long been tightly controlled by a handful of international giants.

Arkema’s patents cover critical aspects of this process: catalyst systems, optimized reaction conditions, and byproduct management. In essence, any company using a similar pathway to produce acrylic acid risks stepping into Arkema’s patent trap. Worse still, such “process patents” are notoriously difficult to design around—you cannot replicate the same outcome without infringing unless you invent an entirely new synthesis route from scratch.

Huayi’s two subsidiaries have built large-scale acrylic acid plants through technology imports or self-developed adaptations, rapidly capturing domestic market share. Their rise directly threatens Arkema’s pricing power and technical dominance in China. Thus, what Arkema frames as “lawful IP enforcement” may well be perceived by others as strategic commercial containment.

From Joint Liability to Targeted Accountability: Arkema’s Tactical Upgrade

The most telling development came on November 14, 2025, when Arkema submitted an amended complaint. Originally demanding joint and several liability from both subsidiaries, it now insists that Shanghai Huayi New Materials alone shoulder the full RMB 430 million, with Guangxi liable only for RMB 110 million.

This shift appears subtle but is tactically astute. First, it precisely targets the operational nerve center. Shanghai Huayi New Materials, as the headquarters entity, controls core decisions on technology, finance, and external partnerships—it is the “brain.” Concentrating liability here aligns with legal logic and maximizes deterrence.

Second, this “primary-secondary” liability structure reveals Arkema’s deep understanding of Chinese corporate hierarchies. It knows that while Guangxi may be the physical production site, ultimate financial backing flows from the parent group. Therefore, striking the upstream decision-maker is the surest path to real impact.

Most importantly, the unchanged total claim amount signals that Arkema has not softened its stance—it may be positioning itself for stronger leverage in settlement talks or final judgment. After all, if infringement is confirmed, this payment would effectively function as a retroactive technology licensing fee, forcing Huayi to acknowledge Arkema’s technical supremacy—even if only implicitly.

Huayi’s Dilemma: Profits on the Line, Technical Gaps Exposed

In its announcement, Huayi maintains a measured tone, stating the case “remains in first-instance proceedings with no judgment yet rendered” and emphasizing “uncertainty regarding the outcome.” But beneath the corporate calm lies a high-stakes existential test.

As of Q3 2025, Huayi Group reported net profit attributable to shareholders of approximately RMB 1.8 billion. If the court rules fully in Arkema’s favor, the RMB 430 million penalty would consume nearly 24% of its annual earnings—a blow severe enough to rattle investor confidence. And if other patents follow suit, Huayi’s expansion trajectory could stall.

More profoundly, this lawsuit lays bare a systemic weakness in China’s chemical sector: strength in engineering scale and cost control, but fragility in foundational research and original patent portfolios. Many firms achieve “local substitution” not through breakthrough innovation, but via “imitation plus optimization.” That works—until it doesn’t.

As one industry insider put it: “While you’re still cooking new dishes with someone else’s old recipe, they’ve already patented the pot.” Arkema’s patents are that pot. They don’t sell the pot or the rice—but they dictate: without this pot, your meal isn’t legitimate.

The Global Chessboard Behind the Lawsuit: Who Defines “Compliance”?

Beneath this legal battle lies a rebalancing of global chemical power. For decades, Western firms built dense “patent thickets” around high-value chemicals—not necessarily to dominate markets, but to enforce invisible barriers through licensing, cross-licensing, and litigation threats.

Chinese companies, meanwhile, thrived on a model of low-cost, rapid replication, and massive scale. This delivered short-term gains but planted long-term vulnerabilities. Now, as Chinese players push into advanced materials, friction is inevitable.

Arkema’s suit against Huayi isn’t just about money—it’s about setting a precedent: anyone entering this arena must respect intellectual property, or pay the price. In that sense, this case could become a watershed moment for China’s chemical industry going global. A win proves independent innovation is possible; a loss might catalyze a nationwide push for original R&D.

Looking Ahead: Pay the Toll—or Break the Wall

Huayi now faces two stark paths: negotiate a settlement and pay ongoing “patent royalties” to keep producing, or fight aggressively—potentially challenging the validity of Arkema’s patents themselves.

The former preserves short-term stability at great cost; the latter is high-risk but potentially transformative. Notably, Chinese tech firms like Huawei and ZTE have successfully invalidated foreign core patents through invalidation proceedings—a playbook Huayi might consider.

For the broader Chinese chemical industry, this crisis is a wake-up call: you can no longer survive by copying homework. Future competition won’t be about who builds the biggest plant or cuts costs the deepest—it will be about who holds the hardest patents, files the most innovations, and sets the global standards.

Note: The disputed acrylic acid capacity accounts for roughly 15% of China’s total output. Any production halt or restriction would trigger ripple effects across multiple downstream sectors.

Epilogue: One Lawsuit, Revealing the “Growing Pains” of Chinese Manufacturing

When a Chinese company gets sued for billions simply for “using a certain method to make a chemical,” it sounds like satire. Yet reality is this cold and unyielding. This isn’t just a courtroom drama—it’s a battle for technological sovereignty.

Whether Huayi survives this ordeal matters not only to its shareholders but to China’s entire ambition to transform from a “manufacturing giant” into an “innovation powerhouse.” True competitiveness has never resided in factories—it lives in laboratories; not on assembly lines, but in patent registries.

This “acrylic acid war” may be just the beginning. More “patent sieges” await Chinese firms bold enough to challenge the status quo. But it is precisely these confrontations that will force them out of comfort zones—and onto a harder, yet brighter, path forward.